학술논문

BRILLIANCE: A Phase 1/2 Single Ascending Dose Study of EDIT-101, an in vivo CRISPR Gene Editing Therapy, in CEP290-Related Retinal Degeneration
Document Type
Journal
Source
HUMAN GENE THERAPY; OCT 1 2021, 32 19-20, pA13-pA13, 1p.
Subject
Language
English
ISSN
15577422